May is designated as Hepatitis Awareness Month, and May 19 is Hepatitis Testing Day. Hepatitis B and hepatitis C, the most common types of viral hepatitis in the United States, can cause chronic infections, and many persons remain unaware of their infection until serious complications occur. In 2016, an estimated 862,000 and 2.4 million persons were living with hepatitis B and hepatitis C, respectively, despite availability of a vaccine and effective treatment for hepatitis B and a cure for hepatitis C (1, 2) .
Although hepatitis A is preventable through vaccination, multiple states have had outbreaks since 2016, with unprecedented large numbers of cases and person-toperson spread (primarily among persons who use drugs or experience homelessness). A report in this issue of MMWR summarizes this resurgence of hepatitis A among unvaccinated adults at risk (3) .
New cases of hepatitis C are also increasing; during 2010-2016, they increased 3.5-fold, mostly among young adults (4) . Recent increases in viral hepatitis infections, many attributed to surges in injection-drug use (4), highlight the importance of acknowledging and combatting the infectious disease consequences of the nation's opioid crisis.
Hepatitis A virus (HAV) is primarily transmitted fecal-orally after close contact with an infected person (1); it is the most common cause of viral hepatitis worldwide, typically causing acute and self-limited symptoms, although rarely liver failure and death can occur (1) . Rates of hepatitis A had declined by approximately 95% during 1996-2011; however, during 2016-2018, CDC received approximately 15,000 reports of HAV infections from U.S. states and territories, indicating a recent increase in transmission (2, 3) . Since 2017, the vast majority of these reports were related to multiple outbreaks of infections among persons reporting drug use or homelessness (4). In addition, increases of HAV infections have also occurred among men who have sex with men (MSM) and, to a much lesser degree, in association with consumption of imported HAV-contaminated food (5, 6 specimens underwent additional testing, of which 197 (87%) had detectable HAV RNA; of the RNA-positive specimens, 76 (39%), 121 (61%), and 0 (0%) tested positive for a genotype IA, IB, or IIIA viral strain, respectively. In comparison, 4,282 specimens were tested by CDC during 2016-2018, of which 3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 (84%), and 57 (<1%) of these specimens were genotype IA, IB, or IIIA, respectively.
Discussion
The number of hepatitis A infections reported to CDC increased during 2016-2018, along with the number of specimens from infected persons submitted to CDC for additional testing. In the past, outbreaks of hepatitis A virus infections occurred every 10-15 years and were associated with asymptomatic children (8) . With the widespread adoption of universal childhood vaccination recommendations (https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1. htm), asymptomatic children are no longer the main drivers of hepatitis A outbreaks (3, 9) . Although the overall incidence rate of HAV infections has decreased within all age groups, a large population of susceptible, unvaccinated adults who were not infected by being exposed to the virus during childhood remain vulnerable to infection by contaminated foods (typically imported from countries with endemic HAV transmission) and recently, on a much larger scale, through behaviors that increase risk for infection in certain vulnerable populations, such as drug use (3). Increasingly, molecular epidemiology is employed by public health laboratories to better characterize hepatitis A transmission patterns. When combined with reliable epidemiologic data, these laboratory data can be used to identify transmission networks and confirm the source of exposure during commonsource outbreaks, facilitating prompt and effective public health response. Historically, genotype IA has been the most common genotype circulating in North and South America. During 2013-2018, HAV genotype IB predominated in the United States. Increasing numbers of genotype IIIA were seen, a genotype that is considered rare in the United States.
Decreasing new infections from hepatitis A virus can be achieved and sustained by maintaining a high level of population immunity through vaccination. There is no universal vaccination recommendation for adults in the United States; however, ACIP does recommend vaccination for adults who plan travel to HAV-endemic countries, MSM, persons who use drugs, persons with chronic liver disease, and recently, persons experiencing homelessness (7) . Continued efforts to increase hepatitis A vaccination coverage among the ACIPrecommended risk groups is vital to halting the current hepatitis A outbreaks and reducing overall hepatitis A incidence in the United States.
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Summary

What is already known about this topic?
Hepatitis A is a vaccine-preventable viral infection of the liver that is primarily transmitted through consumption of microscopic amounts of feces.
What is added by this report?
During 2016-2018, reports of hepatitis A infections in the United States increased by 294% compared with 2013-2015, related to outbreaks associated with contaminated food items, among men who have sex with men, and primarily, among persons who report drug use or homelessness.
What are the implications for public health practice?
Increasing vaccination among groups at risk for hepatitis A infection might halt ongoing outbreaks and prevent future outbreaks.
